Results 61 to 70 of about 741,060 (264)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

BMC Cancer, 2018
Background Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR.
Christina Demuth, Anne Tranberg Madsen, Britta Weber, Lin Wu, Peter Meldgaard, Boe Sandahl Sorensen   +5 more
doaj   +1 more source

Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.

PLoS ONE, 2020
Adenocarcinoma is the most common type of non-small cell lung cancer. Some causative genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon 19 (E19 dels) and a point mutation in E21, are known to have favourable ...
Hee-Young Yoon, Jeong-Seon Ryu, Yun Su Sim, Dojin Kim, Sung Yong Lee, Juwhan Choi, Sojung Park, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang   +9 more
doaj   +1 more source

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6 [PDF]

, 2016
Background\ud \ud - In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma patients, we evaluated feasibility of EGFR mutation detection using circulating cell-free DNA (cfDNA) and
Yamamoto, Nobuyuki, Hou, Mei, Nobuyuki Yamamoto, Neil Gibson, Li, Wei, Hu, Cheng-Ping, Kim, Miyoung, Yi-Long Wu, Kenneth O'Byrne, Tony Mok, O'Byrne, Kenneth, Mei Hou, Yang, James Chih-Hsin, Vera Hirsh, Yunchao Huang, Wei Li, Gibson, Neil, Sequist, Lecia V., James Chih-Hsin Yang, Huang, Yunchao, Cheng-Ping Hu, Lecia V Sequist, Wu, Yi-Long, Sequist, Lecia, Hirsh, Vera, Schuler, Martin, Miyoung Kim, O'Byrne, Kenneth J., Jifeng Feng, Mok, Tony, Lu, Shun, Massey, Dan, Shun Lu, Feng, Jifeng, Dan Massey, Martin Schuler   +35 more
core   +2 more sources

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Profile of the therascreen (R) EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer

, 2017
Introduction: Gefitinib is recently approved by the US Food and Drug Administration as a first-line treatment for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations.
林家齊;楊志新;李日翔, Hsiue, Emily Han-Chung;Lee, Jih-Hsiang;Lin, Chia-Chi;Yang, James Chih-Hsin   +1 more
core   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells [PDF]

, 2011
Background:The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer.
F Solca, Solca, F, D Mackintosh, Guertler, U, Modjtahedi, H, Mackintosh, D, A G Dalgleish, Seddon, AM, Dalgleish, AG, N Ioannou, A M Seddon, U Guertler, Ioannou, N, Dalgleish, A G, H Modjtahedi, Seddon, A M   +15 more
core   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source